Please login to the form below
Pharma and NHS working together for patients - the IBD Registry Industry Working Group
We hear a lot from pharma about patient-centricity these days, and rightly so. But there are many ways of putting this important principle into practice, and they don’t have to be complicated or expensive.
We hear a lot from pharma about patient-centricity these days, and
rightly so. But there are many ways of putting this important principle
into practice, and they don’t have to be complicated or expensive.
Recently, we spoke to members of the IBD Registry Industry Working Group about what they’ve achieved in their first year, and whether or not it’s been worthwhile. It’s a very simple idea: the Registry executive team has clinical and academic expertise aplenty, industry colleagues contribute insights on how best to engage with pharma, and business development strategies to accelerate Registry participation.
The group’s activities have been fruitful, but perhaps more interesting still are the reflections on the experience. Members are proud of the way that companies have set aside commercial rivalries in order to support clinicians and patients, and the Registry chair concluded: “My message to pharma is, more of the same please!”
You can watch the video here: http://dovetailstrategies.com/our-work/case-studies/pharma-and-nhs-working-together-for-patients-the...
Recently, we spoke to members of the IBD Registry Industry Working Group about what they’ve achieved in their first year, and whether or not it’s been worthwhile. It’s a very simple idea: the Registry executive team has clinical and academic expertise aplenty, industry colleagues contribute insights on how best to engage with pharma, and business development strategies to accelerate Registry participation.
The group’s activities have been fruitful, but perhaps more interesting still are the reflections on the experience. Members are proud of the way that companies have set aside commercial rivalries in order to support clinicians and patients, and the Registry chair concluded: “My message to pharma is, more of the same please!”
You can watch the video here: http://dovetailstrategies.com/our-work/case-studies/pharma-and-nhs-working-together-for-patients-the...
Latest content on this profile
- Call for industry innovators to join working group
- The IBD Registry is calling for industry stakeholders with a flair for innovation and collaboration to join its Industry Working Group.
Dovetail
- IBD Registry wins Communiqué award for COVID-19 tool
- The IBD Registry has won a coveted Communiqué award in recognition of its collaborative efforts in creating the COVID-19 IBD Risk Tool for people with inflammatory bowel disease (IBD).
Dovetail
- DOVETAIL & IBD REGISTRY WIN AGILITY AND FLEXIBILITY AWARD AT COMMUNIQUÉ 2021
- The award was the first to be won in Communiqué’s new AGILITY AND FLEXIBILITY category.
Dovetail
- Dovetail partners with Tillotts AG to map management of C. difficile infection in Europe
- Specialist stakeholder engagement consultancy Dovetail, based in London, UK, have announced a new partnership with Tillotts Pharma AG to support the launch of Tillotts’ recent acquisition DIFICLIR™ in the EU.
Dovetail
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Specialist healthcare consultancy Dovetail launches new collaboration skills training in response to client demand.
Dovetail
- Joint working that works
Dovetail
